Cellectis SA (CLLS)
1.87
+0.01
(+0.54%)
USD |
NASDAQ |
Nov 22, 16:00
1.88
+0.01
(+0.53%)
After-Hours: 20:00
Cellectis Cash from Investing (Quarterly): 22.33M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 22.33M |
| June 30, 2024 | -106.43M |
| March 31, 2024 | -2.051M |
| December 31, 2023 | -13.65M |
| September 30, 2023 | -0.30M |
| June 30, 2023 | -1.788M |
| March 31, 2023 | 0.23M |
| December 31, 2022 | -0.163M |
| September 30, 2022 | -0.061M |
| June 30, 2022 | -1.555M |
| March 31, 2022 | -0.982M |
| December 31, 2021 | -0.204M |
| September 30, 2021 | -2.458M |
| June 30, 2021 | 9.634M |
| March 31, 2021 | 0.307M |
| December 31, 2020 | -2.738M |
| September 30, 2020 | 2.278M |
| June 30, 2020 | -5.33M |
| March 31, 2020 | -48.55M |
| December 31, 2019 | -2.533M |
| Date | Value |
|---|---|
| September 30, 2019 | -25.79M |
| June 30, 2019 | -3.089M |
| March 31, 2019 | -4.456M |
| December 31, 2018 | -2.057M |
| September 30, 2018 | 18.38M |
| June 30, 2018 | 19.85M |
| March 31, 2018 | -0.546M |
| December 31, 2017 | -0.513M |
| September 30, 2017 | 6.132M |
| June 30, 2017 | -1.02M |
| March 31, 2017 | -2.815M |
| December 31, 2016 | 47.46M |
| September 30, 2016 | 7.990M |
| June 30, 2016 | -3.233M |
| March 31, 2016 | -105.36M |
| December 31, 2015 | -0.898M |
| September 30, 2015 | -0.0645M |
| June 30, 2015 | -3.585M |
| March 31, 2015 | -3.180M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-106.43M
Minimum
Jun 2024
22.33M
Maximum
Sep 2024
-7.701M
Average
-1.268M
Median
Cash from Investing (Quarterly) Benchmarks
| Edap TMS SA | -1.120M |
| Genfit SA | -- |
| DBV Technologies SA | -0.109M |
| Akari Therapeutics PLC | -- |
| Biodexa Pharmaceuticals PLC | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.829M |
| Cash from Financing (Quarterly) | -4.218M |
| Free Cash Flow | 60.38M |
| Free Cash Flow Per Share (Quarterly) | -0.0663 |
| Free Cash Flow to Equity (Quarterly) | -8.455M |
| Free Cash Flow to Firm (Quarterly) | -6.634M |
| Free Cash Flow Yield | 36.04% |